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Abstract
Background and Objective Abuse of opioid analgesics
has become a public health issue. Some opioid abusers use
intravenous administration to increase the magnitude of
positive reinforcing effects. Intravenous co-administration
of oxycodone with naloxone, an opioid antagonist, may
reduce these rewarding effects and discourage abuse. A 2:1
oxycodone:naloxone (OXN) tablet formulation has been
studied in the USA for the management of moderate-to-
severe chronic pain. Intravenous administration of a 2:1
oxycodone:naloxone solution (sOXN) reflects the oxyco-
done:naloxone ratio found in laboratory studies of OXN
following tampering for intravenous administration. The
objective of this study was to characterize abuse-deterrent
properties of sOXN.
Methods This single-center, double-blind, randomized,
placebo-controlled, active-controlled, crossover study
enrolled nondependent recreational opioid users with
experience using multiple (two or more) routes of admin-
istration. Following demonstration that subjects could
discern between placebo and oxycodone, 24 eligible male
and female subjects were randomized to receive intrave-
nous injections of 0.07 mg/kg oxycodone (OXY), 0.07 mg/
kg oxycodone and 0.035 mg/kg naloxone solution (sOXN),
or matching placebo over three visits. Pharmacokinetics,
pharmacodynamics, safety, and tolerability were assessed
at scheduled times up to 8 h post-dose. Parameters were
computed and statistically compared among treatments.
Results Pharmacokinetics were similar between OXY
and sOXN. Subjects reported significantly fewer rewarding
effects with sOXN compared with OXY; differences
between sOXN and placebo were generally not significant.
sOXN was well tolerated.
Conclusions Significant reductions in drug liking and
other subjective effects following administration of sOXN
compared with OXY indicate that naloxone concentrations
were sufficient to antagonize the effects of oxycodone
when abused by the intravenous route of administration in
opioid-experienced drug users.
Key Points
Significant reductions in the degree of drug liking
and other pharmacodynamic effects following
intravenous administration of oxycodone/naloxone
compared with oxycodone were consistent with the
agonist-antagonist interaction hypothesis.
Naloxone concentrations were sufficient to
antagonize the reinforcing effects of oxycodone
when abused by the intravenous route of
administration in opioid-experienced drug users.
Drug liking reduction by intravenous administration
of oxycodone/naloxone observed in this study may
not represent the situation in the real-world settings.
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1 Introduction
Extended-release opioid analgesics are approved for the
treatment of moderate-to-severe pain with less frequent
dosing than immediate-release opioid analgesics [1]. A
significant public health challenge is to ensure access to
these products while reducing their misuse and abuse [2,
3]. Misuse and abuse of analgesics has numerous adverse
healthcare implications, including psychiatric illness, that
increase the cost burden to insurers [3, 4].
Abusers manipulate opioid formulations to obtain faster
absorption, which can produce a state of euphoria or
‘‘high’’ [5]. For opioid analgesics, illicit administration can
occur by nasal insufflation of crushed pills and intravenous
administration of tablets dissolved in an aqueous medium
[6]. Oxycodone is an opioid analgesic that has been asso-
ciated with manipulation for injection by recreational drug
users, with needle sharing increasing the health risk [6, 7].
Abuse-deterrent strategies include incorporating physi-
cal and chemical barriers, formulating agonist/antagonist
combinations, adding aversive agents, modifying the
delivery system, developing prodrugs, or using combina-
tions of these techniques [2]. However, it is important that
the intended analgesic efficacy of the medication be
maintained regardless of the abuse-deterrent strategy
employed [2].
A combination tablet formulation with controlled-
release oxycodone hydrochloride and naloxone (2:1 ratio)
is currently marketed in 29 countries and has been studied
in the USA for the management of moderate-to-severe
chronic pain. A previous study determined that oxyco-
done/naloxone at a 2:1 ratio had optimal efficacy and
safety compared with other ratios [8]. Naloxone is a
competitive opioid receptor antagonist with low systemic
activity when administered by the oral route because of
low oral bioavailability (B2 %) [9]. In contrast, intrave-
nous administration results in high plasma concentrations
of naloxone, suggesting that the intravenous administra-
tion of this formulation could block the agonist activity of
oxycodone, thereby conferring abuse-deterrent properties
[10].
The purpose of the current study was to evaluate the
abuse potential, pharmacodynamics, pharmacokinetics, and
safety and tolerability of intravenous administration of
oxycodone with naloxone (2:1 ratio) in nondependent,
opioid-experienced, recreational drug users consistent with
recommendations in the US Food and Drug Administra-
tion’s (FDA’s) recent draft guidance [2]. The pharmaco-
kinetics and pharmacodynamics following intravenous co-
administration of oxycodone and naloxone were charac-
terized to evaluate the abuse-deterrent properties of this




This single-center, double-blind, randomized, placebo-
controlled, active-controlled, crossover study was con-
ducted at INC Research Toronto, Toronto, Ontario, Canada
in accordance with the Declaration of Helsinki and its
amendments as outlined by the International Conference on
Harmonisation. Prior to the initiation of the clinical study,
the protocol, consent form, amendments to the protocol,
and advertisements for the recruitment of subjects were
reviewed and approved by the Ontario Institutional Review
Board in Aurora, Ontario, Canada. All subjects provided
written, informed consent prior to the initiation of any
study-related procedures.
This study comprised four phases: screening, qualifica-
tion, treatment, and follow-up. The screening phase was to
confirm that subjects had moderate experience with abuse
of opioids but were not currently physically opioid
dependent, consisting of two visits: visit 1 occurred within
21 days of first administration of study drug, and visit 2
(naloxone challenge test [11]) took place within at least
12 h prior to the qualification phase. In this test, subjects
received an initial dose of 0.2 mg naloxone HCl intrave-
nously followed by a subsequent dose of 0.6 mg if no
evidence of withdrawal (Objective Opiate Withdrawal
Scale [12] score of C3) was observed.
The qualification phase, 3 days in duration, was to
determine whether candidate subjects could (a) tolerate the
effects of oxycodone and (b) discriminate between the
active compound and placebo. Randomized subjects
received either a single intravenous dose of oxycodone
0.07 mg/kg (OXY) or matching placebo with a washout of
24 h. Qualified subjects adequately distinguished between
OXY and placebo [a difference of at least 15 points (30 %)
greater on the 100-point bipolar (i.e., 50 = neutral
response) on a Drug Liking visual analog scale (VAS), and
at least 10 points (20 %) greater on the 100-point bipolar
Overall Drug Liking VAS for OXY compared with pla-
cebo]; and tolerated 0.07 mg/kg oxycodone.
The treatment phase consisted of three visits, each lasting
2 days with one overnight stay. During the treatment phase,
subjects received each of the study drugs by intravenous
administration in a randomized, double-blind fashion. A
follow-up phase completed the study, with subjects returning
for one visit, which was scheduled 3–7 days after the last
administration of the study drug in the treatment phase.
2.2 Subjects
The study population consisted of healthy male and female
subjects, aged 18–55 years, who were nondependent
422 S. V. Colucci et al.
recreational drug users and experienced with multiple
routes (two or more) of opioid administration. Main
inclusion criteria were a body mass index (BMI) of
18.0–29.9 kg/m2 with a minimum weight of 50 kg. Can-
didate subjects must have taken a dose equivalent to 40 mg
oxycodone by any route of administration at least one time
during their lifetime. A negative urine drug test was
required prior to the naloxone challenge and all treatment
visits. Candidates were not excluded from the study if
cannabinoids and benzodiazepines were present in their
system because of the long half-life of the parent molecule
or metabolites. However, urine drug tests for these mole-
cules were required to be negative, stable, or decreasing
during the study. Negative breath alcohol tests were
required at all visits.
Main exclusion criteria included symptoms of withdrawal
on the naloxone challenge test (Objective Opiate With-
drawal score C3) or a self-reported history of dependence
within the previous 2 years, or participation in a rehabilita-
tion program at any time. Subjects were also excluded if they
had any clinically relevant findings in their medical history,
including a history or presence of any significant illness, past
or planned abdominal surgery, a history of hypotension, or
acute asthma or other obstructive airway disease. Addition-
ally, candidates were excluded for consuming[20 cigarettes
per day prior to screening or being unable to abstain from
smoking for at least 10 h. Use of nonprescription medica-
tions, prescription medications, or natural health products
was not permitted, except acetaminophen (B2 g/day), vita-
min or mineral supplements, acceptable forms of birth con-
trol, or hormone replacement within 7 days of the first dose
of study drug or throughout the study.
2.3 Treatment
Subjects received each of the following intravenous treatments
per visit: (1) oxycodone 0.07 mg/kg ? naloxone 0.035 mg/kg
solution (sOXN; Purdue Pharma LP, Wilson, NC, USA); (2)
oxycodone 0.07 mg/kg ? naloxone placebo (OXY); and (3)
placebo (oxycodone placebo ? naloxone placebo; Bard
Pharmaceuticals Ltd, Cambridge, UK). The investigational
products used in the study included: OxyNorm (oxycodone
hydrochloride; NAPP Pharmaceuticals, Cambridge, UK)
10 mg/mL; saline (0.9 % NaCl); and naloxone hydrochloride
1 mg/mL (Sandoz, Montre´al, QC, Canada).
Oxycodone 0.07 mg/kg was selected as the study dose
to produce detectable and significant drug effects in rec-
reational drug users with tolerance to opioids than an
opioid-naı¨ve population [13]. Naloxone 0.035 mg/kg was
selected to simulate the 2:1 ratio that is intended for the
oxycodone/naloxone formulation. Naloxone or placebo
was administered as a bolus injection followed by infusion
of oxycodone or placebo within 1 min.
2.4 Pharmacokinetics and Pharmacodynamics
Pharmacokinetic and pharmacodynamic assessments were
performed over 8 h post-dose. Blood samples were collected
pre-dose and 5 min, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, and 8 h
after treatment administration. Plasma samples were pre-
pared within 60 min of blood draw by centrifugation
(3,000 rpm, 4 C, 10 min) and stored at -20 C (±5 C)
until analysis. The following parameters were estimated:
time to peak exposure (tmax); terminal elimination half-life
(t1/2); peak exposure (Cmax); and area under the concentra-
tion-time curve (AUC). Subjective pharmacodynamic mea-
surements were conducted at pre-dose (except for measures
specifically assessing drug effects) and 5 min, 0.25, 0.5,
0.75, 1, 1.5, 2, 3, 4, 6, and 8 h after treatment administration;
Subjects were asked to quantify treatment effects on
100-point VAS that were either unipolar (i.e., 0 = no effect)
or bipolar (i.e., 50 = neutral response). Bipolar scales
included Drug Liking, Overall Drug Liking, Take Drug
Again, and Alertness/Drowsiness. Unipolar measurements
included: High, Good Effects, Bad Effects, and Any Effects.
Subjective drug value was determined by asking subjects
to make a hypothetical choice between receiving another
dose of sOXN and receiving a specified amount of money
(US$0.25–$50.00). Depending on the answer to the question,
follow-up questions determined the crossover point at which
the subject was indifferent about choosing the drug or
choosing the money. Subjects knew that they would not
actually receive another dose of drug or the money discussed
during this evaluation. This test is adapted from a similar
procedure used by Griffiths and colleagues [14, 15].
Pupillometry was assessed as an objective physiological
measure of opioid effect, using a pupillometer from Neu-
rOptics Inc. (Irvine, CA, USA).
2.5 Bioanalytical Assay
Plasma concentrations of oxycodone were determined by a
validated bioanalysis method using liquid chromatography
with tandem mass spectrometry (LC/MS/MS) following
solid-phase extraction over a concentration range of
0.100–50.0 ng/mL. Plasma concentrations of naloxone
were measured by a validated bioanalysis method using
LC/MS/MS following liquid-liquid extraction over con-
centration range of 10.0–5,000 pg/mL. The internal stan-
dard for oxycodone was oxycodone-D3 and for naloxone
was naloxone-D5. The accuracy and precision of the ana-
lytic method were ensured on the basis of the results from
each analysis of trial samples. For oxycodone, accuracy
averaged 0.500 % [4.40 % relative standard deviation
(RSD)] at 0.200 ng/mL, 1.60 % (3.64 % RSD) at 5.00 ng/
mL and -4.60 % (3.79 % RSD) at 50.0 ng/mL. For nal-
oxone, accuracy averaged 0.00 % (6.75 % RSD) at
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20.0 pg/mL, 0.600 % (4.35 % RSD) at 500 pg/mL and
0.00 % (5.90 % RSD) at 5,000 pg/mL.
2.6 Safety and Tolerability
Evaluations of safety and tolerability included physical
examinations, 12-lead electrocardiogram, continuous car-
diac monitoring (e.g., pulse rate, % oxygen saturation),
vital signs, clinical laboratory tests, medication history, and
adverse events (AEs). AEs were recorded during the period
from the signing of the informed consent form through the
follow-up visit. AEs were observed and categorized by
volunteered signs or symptoms, on clinical assessment, and
through nonleading questions at study visits.
2.7 Statistical Plan
Three study populations were defined. The pharmacoki-
netic population comprised all subjects who received one
dose of study drug during the treatment phase and had
evaluable pharmacokinetic data. All subjects who com-
pleted all visits of the treatment phase and did not have any
protocol violations made up the pharmacodynamic popu-
lation. The safety population included all subjects who
received one dose of the study drug during the treatment
phase. The sample sizes were not determined on the basis
of statistical calculation, but as a suitable sample size based
on previous studies of this type [13].
Descriptive statistics were used to summarize all phar-
macokinetic and pharmacodynamic data. The pharmaco-
dynamic endpoints for the treatment phase were analyzed
with a mixed-effect model for crossover study. For each
model, data were computed to determine the means, 95 %
confidence intervals, and p values for treatments and the
differences between treatments. The contrasts to assess the
abuse potential for sOXN included: sOXN vs. placebo,
OXY vs. placebo, and sOXN vs. OXY. The calculation of
the percent reduction in Drug Liking VAS maximum effect
(Emax) between sOXN and OXY was developed based on
the responder analysis described in recent guidance from
the US FDA [2].
Statistical analyses were performed with SAS (release
9.2, SAS Institute, Cary, NC, USA). Pharmacokinetic
calculations were completed with WinNonLin (version
5.2, PharSight Corporation, Sunnyvale, CA, USA).
3 Results
3.1 Disposition and Demographics
Forty-two subjects were eligible for the qualification phase.
Twenty-four of these 42 subjects (57.1 %) successfully met
the criteria for qualification, and were enrolled in the
treatment phase. Among these 24 subjects, the mean age
was 34.9 years, the proportion of male subjects was
87.5 %, and the majority of subjects were white (87.5 %).
All subjects had used opioids in the past with 79 % having
used cannabinoids. Other drug use was less prevalent.
Twenty-two subjects completed the study.
3.2 Pharmacokinetics
Mean observed Cmax of oxycodone was 98.6 ng/mL after
sOXN administration and 83.1 ng/mL after OXY (Fig. 1a).
The mean AUC of oxycodone was 116.4 ngh/mL after
sOXN and 114.7 ngh/mL after OXY, respectively. Median
tmax and median t1/2 after sOXN vs. OXY were 0.05 and
0.05 h, respectively, and 3.5 and 3.4 h, respectively. After
sOXN administration, the mean Cmax for naloxone was
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Fig. 1 a Mean plasma oxycodone concentrations (ng/mL) over time.
Oxycodone was administered intravenously as oxycodone 0.07 mg/
kg ? naloxone 0.035 mg/kg (sOXN; n = 24) or oxycodone 0.07 mg/
kg ? placebo (OXY; n = 23). b Pharmacokinetics of naloxone (ng/
mL) over time. Naloxone was administered intravenously as oxyco-
done 0.07 mg/kg ? naloxone 0.035 mg/kg (sOXN; n = 24)
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(Fig. 1b). The median tmax for naloxone was 0.05 h with a
median t1/2 of 1.2 h.
3.3 Pharmacodynamics
The mean VAS scores over time for Drug Liking ‘‘at this
moment’’ were higher after OXY administration than after
sOXN or placebo administration (Fig. 2). The Emax scores
were 96.4 for OXY, 56.5 for sOXN, and 48.7 for placebo.
The differences in each pairwise comparison were signifi-
cant: OXY vs. placebo, p \ .001; sOXN vs. OXY,
p \ .001; and sOXN vs. placebo, p = .05.
A responder analysis using Emax of Drug Liking ‘‘at this
moment’’ VAS was conducted in 21 subjects who had
evaluable data with sOXN and OXY during the treatment
phase. In all, 95.2 % of subjects reported a C50 %
reduction in the Drug Liking VAS for sOXN compared
with OXY alone (Fig. 3).
In end-of-treatment assessments, the global measures of
Overall Drug Liking VAS and Take Drug Again VAS were
highest after OXY administration compared with sOXN
and placebo (Fig. 4; Table 1). The p values for pairwise
differences in these VAS scores were statistically signifi-
cant for sOXN vs. OXY and OXY vs. placebo (p B .001),
but not for sOXN vs. placebo. The mean scores for Sub-
jective Drug Value were US$25.06 for OXY, US$3.38 for
sOXN, and US$0.86 for placebo. The differences in value
for placebo vs. OXY and sOXN vs OXY were statistically
significant (p \ .001) but not the difference in placebo vs.
sOXN (p = .31).
Mean Good Effects VAS scores over time are shown in
Fig. 5. For Emax scores of Good Effects VAS and Feeling
High VAS, the differences for placebo vs. OXY and sOXN
vs OXY were statistically significant (p \ .001), but there
was no significant difference between placebo and sOXN.
The mean Emax of Bad Effects VAS and Feeling Sick VAS
were low after all treatments and the overall treatment
effects for these scores were not significant. The mean Emin
of Drowsiness/Alertness VAS was lowest after OXY
administration and similar between sOXN and placebo.
The differences between OXY and sOXN or placebo were
significant (p \ .001 and p = .04, respectively), whereas
the difference between sOXN and placebo was not
(p = .91).
Mean pupil diameter over time is shown in Fig. 6. After
OXY administration, the maximum pupil diameter con-
striction was 2.8 mm [standard deviation (SD) 0.7 mm].
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Fig. 2 Mean at the Moment
Drug Liking VAS scores over
time for OXY, sOXN, or
placebo (n = 22). sOXN
simulated oxycodone/naloxone,
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Fig. 3 Percentage of nondependent opioid drug users indicating a
reduction in Drug Liking VAS Emax following administration of
sOXN (0.07 mg/kg oxycodone and 0.035 mg/kg naloxone) compared
with OXY (0.07 mg/kg oxycodone; n = 21). Emax maximum effect,
sOXN simulated oxycodone/naloxone, OXY oxycodone
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maximum pupil constriction of 1.1 mm (SD 0.7 mm),
which was similar to the maximum pupil constriction of
1.1 (SD 0.6 mm) after placebo administration. The least-
squares mean difference was -1.62 mm for placebo vs.
OXY (p \ .001) and 1.59 for sOXN vs. OXY (p \ .001).
No significant difference was found between placebo and
sOXN.
3.4 Safety and Tolerability
The overall incidence of treatment-emergent adverse
events (TEAEs) in the safety population (n = 23/24) after
study drug administration was 20.8 % with placebo,
29.2 % with sOXN, and 95.7 % with OXY. The most
common TEAEs occurring during this study were euphoric
mood, feeling hot, somnolence, and headache (Table 2).
There were two incidents of ventricular tachycardia,
considered a serious TEAE. One event occurred following
administration of sOXN, and the other after administration
of placebo; the latter subject discontinued the treatment
phase because of the TEAE. Both events were deemed
medically important, mild in severity, and possibly related









































Fig. 4 End-of-treatment balance measures, administered at 8 h post-
dose (n = 22). Bars indicate mean (SD) of each measure. For Overall
Drug Liking VAS (left panel), Take Drug Again VAS (center panel),
and Subjective Drug Value (right panel), p \ 0.001 for OXY vs. both
sOXN and placebo. sOXN simulated oxycodone/naloxone, OXY
oxycodone, VAS visual analog scale, SD standard deviation
Table 1 Summary of VAS scores
Parameter Mean (SD) Emax p value from pairwise comparison
OXY sOXN Placebo OXY vs sOXN sOXN vs Placebo OXY vs Placebo
Overall Drug Likinga 79.5 (26.7) 49.5 (18.5) 46.0 (15.0) 0.001 0.46 \0.001
Take Drug Againa 82.0 (28.4) 37.0 (29.0) 34.5 (24.2) \0.001 0.42 \0.001
Good Effects 94.0 (21.2) 20.0 (34.9) 2.7 (11.7) \0.001 0.07 \0.001
High 94.6 (21.3) 19.6 (33.4) 2.9 (11.7) \0.001 0.05 \0.001
Bad Effectsb 11.5 (22.4) 7.5 (21.2) 2.9 (12.3) – – –
Feeling Sickb 10.3 (23.0) 7.5 (23.2) 3.0 (10.8) – – –
Drowsiness/Alertnessc 32.1 (25.1) 47.3 (23.4) 47.2 (25.0) \0.001 0.91 0.04
a End-of-treatment assessments
b Treatment differences were not assessed because overall treatment effect was not significant
c Emin values used for Drowsiness/Alertness
Emax maximum effect, Emin minimum effect, OXY oxycodone 0.07 mg/kg, sOXN simulated oxycodone 0.07 mg/kg ? naloxone 0.035 mg/kg, SD
standard deviation, VAS visual analog scale [either unipolar (i.e., 0 = no effect) including High, Good Effects, Bad Effects or bipolar (i.e.,
50 = neutral response) including Overall Drug Liking, Take Drug Again, and Drowsiness/Alertness]
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4 Discussion
Intravenous administration of oxycodone alone (OXY) or
in combination with naloxone (sOXN) resulted in similar
plasma concentration profiles over time, but the pharma-
codynamic effects, safety, and tolerability of sOXN were
similar to placebo. Subjects experienced significantly less
drug liking and other measures of abuse potential following
administration of sOXN compared with OXY. These
observations suggest that the coadministration of a
l-receptor antagonist at the current ratio is sufficient to block
the agonist effects of oxycodone. The lower abuse potential
of the 2:1 oxycodone/naloxone of sOXN observed in this
study is anticipated to contribute to a reduction in OXN abuse
liability in real-world settings. Because numerous complex
factors affect real-world abuse liability, post-marketing
epidemiologic studies will be needed to assess the actual
impact of OXN’s abuse deterrent properties.
This placebo- and active-controlled trial measured the
pharmacokinetic and pharmacodynamic effects of intra-
venous administration of sOXN to characterize abuse
properties in an opioid-experienced recreational popula-
tion. Adhering closely to study-design guidance from the
US FDA, recreational drug users were enrolled after con-
firmation of their ability to distinguish between placebo
and an active compound. All subjects also passed the

































Fig. 5 Mean Good Effects
VAS scores over time for OXY,
sOXN, and placebo (n = 22).
sOXN simulated oxycodone/


















0 2 4 6 8
Time postdose (h)
sOXN OXYPlacebo
Fig. 6 Mean pupil diameter (mm) over time for OXY, sOXN, and
placebo (n = 22). (Pupil size measured at predose, 0.083, 0.25, 0.5,
0.75, 1, 1.5, 2, 3, 4, 6, and 8 h post-dose.) sOXN simulated
oxycodone/naloxone, OXY oxycodone








Any 5 (20.8) 7 (29.2) 22 (95.7)
Feeling hot 1 (4.2) 4 (16.7) 9 (39.1)
Headache 2 (8.3) 4 (16.7) 1 (4.3)
Somnolence 0 (0) 4 (16.7) 7 (30.4)
Euphoric mood 0 (0) 2 (8.3) 17 (73.9)
Nausea 0 (0) 1 (4.2) 2 (8.7)
Dizziness 0 (0) 0 (0) 3 (13.0)
Pruritus
generalized
0 (0) 0 (0) 3 (13.0)
Vision blurred 0 (0) 0 (0) 2 (8.7)
Pruritus localized 0 (0) 0 (0) 2 (8.7)
Note: Values are expressed as n (%)
OXY oxycodone 0.07 mg/kg, sOXN simulated oxycodone 0.07 mg/
kg ? naloxone 0.035 mg/kg
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phase, indicating that they were not opioid dependent. A
limitation of this study was the dose ratio selection. An
oxycodone dose of 0.07 mg/kg (1-min infusion) was
selected based on previous clinical experience in the same
population [13]. Naloxone was administered at a dose of
0.035 mg/kg according to the intended OXN ratio of 2:1.
However, this dose ratio may not represent the situation in
real-world settings. Abusers likely crush tablets, extract
oxycodone from combined tablets, and dissolve the
extracts in an aqueous medium for a single intravenous
administration, which may have higher or lower concen-
trations or different ratios than the study preparation,
depending on the method of extraction. However, labora-
tory testing indicates that the inactivation of naloxone and
the separation of oxycodone from naloxone are difficult to
achieve (unpublished data).
Assessments of drug liking, subjective drug value, and
other measurements proved valuable in assessing medica-
tions for potential misuse [2]. End-of-treatment and time-
course measurements of pharmacodynamic effects showed
significant differences between OXY and sOXN adminis-
tration, but not when sOXN was compared with placebo.
Objective assessment by pupillometry supported these
subjective responses, as well as the low incidence of
euphoric mood associated with sOXN compared with
OXY, indicating that naloxone antagonized the central
activity of oxycodone. Low scores for Bad Effects VAS
and Feeling Sick VAS for all treatments indicated minimal
negative effects, as well. The current study suggests that
sOXN has significantly fewer rewarding effects, which
might make the tablet formulation less appealing to rec-
reational drug users when crushed and dissolved for
injection. Formulations that can be manipulated to produce
a faster onset of action to quickly attain peak rewards have
the highest likelihood for abuse [2].
Although the pharmacodynamic effects of sOXN were
similar to placebo, sOXN and OXY demonstrated similar
oxycodone exposures. Pharmacodynamic VAS scores after
OXY administration had peak and duration of effects
consistent with oxycodone concentration profiles. sOXN
administration resulted in significant attenuation of oxy-
codone Drug-Liking VAS ratings compared with OXY.
Overall, sOXN was well tolerated and the AE profile was
similar to known effects of opioid agonists. The most
common AEs following OXY and sOXN administration
included euphoric mood, feeling hot, and somnolence,
although the incidence of these events was lower after
sOXN than OXY, and lowest following placebo adminis-
tration. These results suggest that naloxone significantly
reduces, but does not completely eliminate, the central
effects of oxycodone when co-administered intravenously.
The overall incidence of these effects may be affected by
the central exposure to naloxone.
Prescription opioid analgesics are an important compo-
nent of modern pain management. However, their abuse
and misuse represent a serious and growing public health
issue. The development of abuse deterrent opioid analgesic
formulations represents one important approach to
addressing this public health problem. [7]. Some recrea-
tional drug users report greater reinforcing effects follow-
ing intravenous opioid administration, likely the result of
the more rapid rise of drug concentrations in the central
nervous system [7]. Intravenous administration of drugs is
associated with increased health risks [6, 7]. An oxycodone
formulation such as OXN that limits the reinforcing effects
of oxycodone in the setting of intravenous abuse may,
along with other efforts, lead to lower abuse liability in
real-world settings. The present study demonstrated sig-
nificantly lower drug-liking after sOXN, which is consis-
tent with the agonist-antagonist interaction hypothesis. In
addition to the present findings, we have shown in related
research that OXN has reduced abuse potential following
intranasal administration [16]. These findings suggest that
the naloxone component of OXN confers meaningful
abuse-deterrent properties in settings of intranasal and
intravenous abuse [17].
Agonist/antagonist abuse-deterrent formulations have
been used for other opioid agonists. For example, naloxone
has been formulated with the partial opioid agonist bupr-
enorphine (Suboxone) in a 4:1 ratio of buprenorphine to
naloxone to decrease the abuse, misuse, and diversion of
buprenorphine monotherapy. In one study, intramuscular
injection of the buprenorphine/naloxone combination pro-
duced dose-related increases in opioid withdrawal in opi-
oid-dependent individuals [18]. Similarly, another study
demonstrated that subjects were less willing to pay for the
intravenous buprenorphine/naloxone combination com-
pared with either buprenorphine alone or heroin [19].
These results are consistent with the current study wherein
participants were less willing to pay for the oxycodone/
naloxone combination compared with oxycodone alone.
Nevertheless, the addition of naloxone might provide yet
another deterrent to oxycodone abuse.
5 Conclusions
Significant reductions in the degree of drug liking and other
pharmacodynamic measures after administration of sOXN
compared with OXY indicate that naloxone concentrations
were sufficient to antagonize the effects of oxycodone
when abused by the intravenous route of administration in
opioid-experienced drug users. Post-marketing epidemiol-
ogic data from a variety of sources will be needed to assess
the effects of OXN’s abuse deterrent properties on its abuse
in real-world settings.
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